相关实验视频

Updated: Jul 12, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

抗血管性纳米材料在瘤治疗中的新兴应用

Bicai Tang¹, Wenjuan Ma¹, Yunfeng Lin¹

¹State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, PR China; Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China; Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, PR China.

Journal of controlled release : official journal of the Controlled Release Society

|October 23, 2023

概括

纳米技术提供先进的抗血管性纳米材料,以克服传统癌症疗法的局限性. 这些新型药物显示出改善瘤向和增强瘤治疗治疗结果的前景.

科学领域:

在瘤学瘤学.
生物医学工程生物医学工程
纳米技术纳米技术

背景情况:

瘤细胞劫持血管生成,新血管形成的过程,进行不受控制的生长.
传统的抗血管生成疗法面临着诸多挑战,包括针对性不佳,生物可用性低,有效性有限.
在癌症治疗中,急需改进抗血管生成策略.

研究的目的:

审查病态血管生成在癌症中的作用.
讨论当前抗血管生成药物的局限性.
突出纳米材料在抗血管性癌症治疗中的潜力.

主要方法:

关于瘤血管新生和抗血管新生疗法的科学文献的综述.
分析纳米材料在抑制瘤血管化的应用.
讨论该领域的挑战和未来方向.

主要成果:

与传统药物相比,纳米材料提供了增强的向性,减少了副作用,并提高了疗效.
纳米技术为开发下一代抗血管性癌症治疗提供了一个有前途的平台.
目前面临的挑战包括优化交付和确保基于纳米材料的疗法的长期安全性.

结论:

纳米材料在治疗癌症的抗血管原体疗法方面取得了重大进展.
需要进一步的研究和开发才能充分发挥这些药物的潜力.
预计抗血管性纳米材料将在未来的瘤治疗中发挥关键作用.

关键词:

血管新生的产生.抗血管生成的作用抗瘤疗法是一种抗瘤治疗.纳米材料是一种纳米材料.纳米治疗药物纳米治疗药物瘤治疗瘤疗法

更多相关视频

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...